Adrenocortical steroids increase renal thiazide diuretic receptor density and response.
The density of the rat renal pharmacologic receptor for thiazide-type diuretics, as quantitated by the maximal specific binding of (3H)metolazone, decreased to one-third normal after adrenalectomy. Selective glucocorticoid (dexamethasone or RU-28362) replacement increased thiazide receptor density to or above the normal level over the dose range of steroid that decreased thymus weight, which served as a bioassay for glucocorticoid activity. Mineralocorticoid (fludrocortisone or aldosterone), in doses that did not decrease thymus weight, also increased thiazide diuretic receptor density to or above normal. The addition of glucocorticoid (RU-28362) to maximal aldosterone increased thiazide receptor above that produced by aldosterone alone and to threefold normal. Similarly, the addition of aldosterone to high-dose RU-28362 also increased thiazide receptor density above that produced by the glucocorticoid alone and to threefold normal. Hence, the effects of glucocorticoids and mineralocorticoids appeared to be additive. The increase in renal thiazide receptor density produced by fludrocortisone, at a dose that elicited both mineralocorticoid and glucocorticoid effects, was unrelated to the basal (prethiazide) renal excretion of sodium, potassium, chloride, or calcium. However, fludrocortisone-pretreated animals responded to bendroflumethiazide with a greater natriuresis than did controls. In addition, the magnitudes of the thiazide-elicited natriuresis and chloriuresis correlated significantly with thiazide receptor. It was concluded that both the density of the renal thiazide receptor and the quantity of sodium and chloride reabsorbed by the thiazide-sensitive Na-Cl cotransporter in the kidney are under adrenocortical regulation.
Chen
Z
Z
Department of Medicine, School of Medicine, University of California, San Diego, La Jolla 92093-0623.
Vaughn
D A
DA
Blakely
P
P
Fanestil
D D
DD
D000315:Adrenalectomy; D000450:Aldosterone / Q000008:administration & dosage / Q000494:pharmacology*; D000732:Androstanols / Q000494:pharmacology; D000818:Animals; D001539:Bendroflumethiazide / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002352:Carrier Proteins / Q000187:drug effects*; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004232:Diuretics; D005438:Fludrocortisone / Q000494:pharmacology; D007668:Kidney / Q000737:chemistry* / Q000187:drug effects; D007684:Kidney Tubules / Q000378:metabolism; D008297:Male; D008788:Metolazone / Q000378:metabolism; D011188:Potassium / Q000097:blood / Q000652:urine; D051381:Rats; D011921:Rats, Inbred WKY; D017207:Rats, Sprague-Dawley; D011955:Receptors, Drug / Q000187:drug effects*; D012965:Sodium Chloride / Q000097:blood / Q000652:urine; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology*; D049992:Sodium Chloride Symporters; D064486:Solute Carrier Family 12, Member 3; D027981:Symporters; D013950:Thymus Gland / Q000187:drug effects
D000732:Androstanols; D002352:Carrier Proteins; D004232:Diuretics; D011955:Receptors, Drug; C578876:Slc12a3 protein, rat; D049993:Sodium Chloride Symporter Inhibitors; D049992:Sodium Chloride Symporters; D064486:Solute Carrier Family 12, Member 3; D027981:Symporters; C064415:thiazide receptor; D012965:Sodium Chloride; D000450:Aldosterone; D001539:Bendroflumethiazide; C049154:11,17-dihydroxy-6-methyl-17-(1-propynyl)androsta-1,4,6-triene-3-one; D003907:Dexamethasone; D011188:Potassium; D008788:Metolazone; D005438:Fludrocortisone